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Abstract
Purpose: Cardiac radiation exposure is associated with an increased rate of adverse cardiac events in patients receiving radiation therapy for locally advanced non-small cell lung carcinoma (NSCLC). Previous analysis of practice patterns within the Michigan Radiation
Oncology Quality Consortium (MROQC) revealed 1 in 4 patients received a mean heart dose >20 Gy and signiﬁcant heterogeneity
existed among treatment centers in using cardiac dose constraints. The purpose of this study is to analyze the effect of education and initiation of standardized cardiac dose constraints on heart dose across a statewide consortium.
Sources of support: MROQC is ﬁnancially supported by Blue Cross Blue Shield of Michigan (BCBSM) and the Blue Care Network of Michigan as
part of the BCBSM Value Partnerships Program.
Disclosures: Authors report grant funding and/or salary support from Blue Cross Blue Shield of Michigan and Blue Care Network (Drs Jolly, Matuszak, and Schipper); Varian Medical Systems (Drs Matuszak and Mosvas); Phillips (Dr Mosvas); and ViewRay (Dr Mosvas). Authors report consulting
fees from Innovative Analytics (Dr Schipper); leadership or a ﬁduciary role for Varian Medical Systems (Dr Jolly) and AstraZeneca (Dr Jolly); a lung
phantom patent (Dr Mosvas); and support for meeting attendance from AstraZeneca (Dr Dominello). All other authors have no disclosures to declare.
The authors are not authorized to share MROQC data. The data are individually owned by the member institutions of MROQC.
* Corresponding author: Shruti Jolly, MD; E-mail: shrutij@med.umich.edu
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Methods and Materials: From 2012 to 2020, 1681 patients from 27 academic and community centers who received radiation
therapy for locally advanced NSCLC were included in this analysis. Dosimetric endpoints including mean heart dose (MHD),
mean lung dose, and mean esophagus dose were calculated using data from dose-volume histograms. These dose metrics were
grouped by year of treatment initiation for all patients. Education regarding data for cardiac dose constraints ﬁrst occurred in
small lung cancer working group meetings and then consortium-wide starting in 2016. In 2018, a quality metric requiring mean
heart dose <20 Gy while maintaining dose coverage (D95) to the target was implemented. Dose metrics were compared before
(2012-2016) versus after (2017-2020) initiation of interventions targeting cardiac constraints. Statistical analysis was performed
using the Wilcoxon rank sum test.
Results: After education and implementation of the heart dose performance metric, mean MHD declined from an average of 12.2 Gy
preintervention to 10.4 Gy postintervention (P < .0001), and the percentage of patients receiving MHD >20 Gy was reduced from
21.1% to 10.3% (P < .0001). Mean lung dose and mean esophagus dose did not increase, and target coverage remained unchanged.
Conclusions: Education and implementation of a standardized cardiac dose quality measure across a statewide consortium was associated with a reduction of mean heart dose in patients receiving radiation therapy for locally advanced NSCLC. These dose reductions
were achieved without sacriﬁcing target coverage, increasing mean lung dose, or increasing mean esophagus dose. Analysis of the clinical ramiﬁcations of the reduction in cardiac doses is ongoing.
Ó 2022 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Introduction
Radiation therapy remains an integral component of
the treatment of locally advanced non-small cell lung carcinoma (NSCLC). Recent evidence indicates that mean
heart dose (MHD) is independently associated with an
increase in the rate of adverse cardiac events in this population, with increased risk of grade ≥ 3 cardiac events
within 24 months after therapy.1 Subsequent analysis of
practice patterns in a combination of academic and community settings revealed substantial heterogeneity in cardiac dose constraints.2 In response to this, monthly
working groups were formed within the Michigan Radiation Oncology Quality Consortium (MROQC) with the
goal of educating providers about the importance of minimizing cardiac radiation dose, and a standardized cardiac
dose constraint was implemented. The purpose of this
study was to determine whether adoption of the heart
dose education initiative and initiation of a standardized
cardiac dose constraint are associated with improved
mean heart dose, and to assess the effect of this constraint
on target coverage and dose to other organs at risk
(OARs).

with access to treatment Digital Imaging and Communications in Medicine to evaluate tumor and normal tissue
contours. This was followed by a discussion at the annual
consortium-wide meeting in 2016 highlighting the data
supporting the importance of heart dose constraints. A
representative from each clinical site is required to attend
this consortium-wide meeting and is tasked with relaying
the information discussed back to their respective clinics.
In 2018, a quality metric requiring mean heart dose <20
Gy while maintaining dose coverage (D95) to the target
was implemented. Planning target volumes (PTVs) were
also calculated from each dose-volume histogram, and
dose coverage was calculated as minimum dose to 95%
PTV (D95%[Gy]).
Dose metrics were compared before (2012-2016) and
after (2017-2019) initiation of interventions targeting cardiac constraints. Continuous variables including MHD
were compared between periods using the Wilcoxon rank
sum test, a nonparametric analog to the 2-sample t test.
Binary variables such as the indicator for MHD >20 Gy
were compared between periods using x2 tests for 2 proportions. Statistical analysis was performed using SAS V,
and statistical signiﬁcance was deﬁned as 2-sided P < .05.

Results
Methods and Materials
Cardiac dose
In the state of Michigan, 1681 patients from 27 academic and community centers who received deﬁnitiveintent radiation therapy either alone or with concurrent
chemotherapy for locally advanced NSCLC between 2012
and 2020 were included in this analysis. Dosimetric endpoints were calculated using data from dose-volume histograms. These dose metrics were grouped by year of
treatment initiation for all patients.
Education regarding data for cardiac dose constraints
ﬁrst occurred in lung cancer working group meetings
designed to evaluate lung cancer speciﬁc quality measures

MHD was calculated for each patient and averaged for
all patients treated in a given year to derive average
MHD. Average MHD and average heart V30 per year are
represented in Figure 1. For 4 years before initiation of
the MROQC education initiative (2012-2016), the average
MHD was 12.2 Gy. After targeted education and initiation
of a standardized cardiac dose constraint (2017-2020),
average MHD in this cohort of patients fell to 10.4 Gy (P
< .0001). Other common cardiac dosimetric parameters
improved as well, with average heart V30[%] improving
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(A) Annual average mean heart dose (MHD) and (B) heart V30 for patients being treated within the statewide
consortium from 2012 to 2020. (C) Comparison of average MHD, heart V30, heart V5, and percent of patients with MHD
>20 Gy for patients treated before (2012-2016) and after (2017-2020) heart constraint initiative.

Fig. 1

from 17.8% for the period 2012 to 2016 to 12.5% from
2017 to 2020 (P < .0001), and the percentage of patients
receiving MHD >20 Gy improving from 21.1% to 10.3%
(P < .0001). Average heart V5[%] remained unchanged at
47.7% from 2012 to 2016 and 47.2% from 2017 to 2020
(P = .78).

Target coverage
Trends involving the average volume of PTV and PTV
coverage were analyzed (Fig. 2). Average PTV volume did
not change signiﬁcantly over time, with PTV averaging
414 cc from 2012 to 2016 and 441 cc from 2017 to 2020
(P = .10). PTV coverage was assessed by calculating minimum dose to 95% PTV for each case, then averaging by
year as previously discussed. From 2012 to 2016, the average minimum dose to 95% PTV was 58.2 Gy, which
remained unchanged at 58.2 Gy for patients treated 2017
to 2020 (P = .99).

Exposure of OARs
Established dosimetric constraints for other thoracic
OARs were analyzed, including mean lung dose (MLD),
lung V20[%], average esophageal dose, and esophagus

D2cc [Gy] (Fig. 3). For patients treated 2012 to 2016, average MLD and lung V20[%] were 14.7 Gy and 24.9%,
respectively, compared with 14.3 Gy and 24.6%, respectively, for patients treated 2017 to 2020 (P = .08 for MLD,
P = .74 for lung V20[%]). Average lung V5[%] increased
slightly from 52.3% from 2012 to 2016 to 56% from 2017
to 2020. In the 2012 to 2016 cohort, 94.1% of patients met
the lung V20[%] constraint of 35%, compared with 91.8%
of patients treated from 2017 to 2020 (P = .11). The average esophagus dose for patients treated 2012 to 2016 was
22.1 Gy, compared with 20 Gy for those treated 2017 to
2020 (P < .0001). Point dose to the esophagus, as measured by D2cc [Gy] did not signiﬁcantly differ, averaging
52.2 Gy in those treated 2012 to 2016 compared with 52.4
Gy in those treated 2017 to 2020 (P = .71).

Treatment modality
The proportion of treatment plans using intensity
modulated radiation therapy (IMRT) was analyzed
(Fig. 4). The rate of IMRT use increased over time, from
61.4% in the 2012 to 2016 cohort to 84.8% in the 2017 to
2020 cohort (P < .0001). MHD in the 2012 to 2016 and
2017 to 2020 cohorts were analyzed adjusting for treatment modality. Among 3-dimensional (3D) conformal
treatment plans, MHD decreased from 12.2 Gy in the
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Fig. 2 (A) Annual average planning target volume (PTV) and (B) minimum dose to 95% PTV for patients being treated
within the statewide consortium from 2012 to 2020. (C) Comparison of average PTV and minimum dose to 95% PTV for
patients treated before (2012-2016) and after (2017-2020) heart constraint initiative (C).

pre-2017 cohort to 9 Gy in the 2017 to 2020 cohort
(P = .003). Similarly, among IMRT treatment plans,
MHD decreased from 12.1 Gy in the pre-2017 cohort to
10.6 Gy in the 2017 to 2020 cohort (P = .002)

Discussion
In this analysis of patients treated across a statewide
consortium, MHD, heart V30 Gy, and the proportion of
patients receiving >20 Gy MHD all decreased in the years
after directed education and standardized heart dose constraint implementation. This was achieved without sacriﬁcing target coverage, with the average minimum dose to
95% PTV being 58.2 Gy both before and after constraint
standardization. Average mean lung dose, lung V20, and
esophageal D2cc were unchanged, with modest improvement in mean esophageal dose. The proportion of patients
meeting lung constraints did not signiﬁcantly change,
though a slight increase in average lung V5 was observed.
The increasing availability of highly conformal treatment techniques is likely to inﬂuence the ability to meet
both target and OAR dosimetric priorities during treatment planning. Accordingly, analysis of IMRT utilization
revealed an increase from 61.4% to 84.8% in the 2012 to
2016 and 2017 to 2020 cohorts, respectively. To account
for this, average MHD for the preintervention and postintervention cohorts were assessed adjusting for treatment
modality, revealing a decrease in average MHD postintervention in both patients treated with 3D and IMRT. The
magnitude of average MHD decease was larger in the
cohort treated with 3D conformal radiation therapy,

possibly reﬂecting progressive limitation of this technique
to targets distant from the heart.
Recent studies have demonstrated an association
between radiation dose to the heart and future risk of
major adverse cardiac events (MACE) in patients being
treated with radiation therapy as part of deﬁnitive-intent
treatment for locally advanced NSCLC1,3 and a strong
correlation between heart dose and overall survival in the
setting of postoperative radiation.4 This occurs despite the
competing risk of cancer-associated mortality, and therefore bears consideration when performing radiation planning for NSCLC. The data herein suggest that, on
average, careful consideration of cardiac dose constraints
can facilitate meaningful dose reduction without sacriﬁcing tumor coverage in this population.
The ﬁndings from this cohort analysis emphasize the
importance of leveraging data from a large statewide consortium to standardize quality of treatment. Multiple
recent studies from this consortium have contributed to
quality improvement through the analysis of practice patterns,2,5-7 racial disparities,8 and patient-reported outcomes9 of patients receiving radiation therapy in the state
of Michigan for a wide variety of disease sites. These ﬁndings are propagated throughout the involved treatment
centers and continually reﬁne the quality of radiation
treatment delivered to patients in the state of Michigan.
One limitation to this study is the unknown clinical
effect of reducing mean heart dose in this cohort of
patients. Although previous studies have indicated a correlation between MHD and 24-month risk of MACE,1
ongoing analyses of this patient cohort are required to
assess whether the reduction in MHD in this study
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(A) Annual average mean lung dose, (B) average lung V20, (C) average esophageal dose, and (D) average esophagus dose for patients being treated within the statewide consortium from 2012 to 2020. (E) Comparison of annual average
mean lung dose, average lung V20, average lung V5, percentage of patients receiving lung V20 <35%, average esophageal
dose, and average esophagus D2cc for patients treated before (2012-2016) and after (2017-2020) heart constraint
initiative.

Fig. 3

population is associated with a corresponding reduction
in cardiac events.
There also remains uncertainty within the ﬁeld as to
which dosimetric constraint best predicts future risk of
MACE. Multiple studies have demonstrated the importance of mean heart dose in this setting,1,3,10,11 but recent
efforts to identify the cardiac substructures most at risk
have identiﬁed left anterior descending artery (LAD) V15

Gy and left ventricle V15 Gy as independent predictors of
MACE.12 Further, subsequent analysis of the previously
mentioned cohort revealed discordance between MHD
and LAD V15 Gy,13 indicating that MHD is not an adequate surrogate of dose to cardiac substructures. Further
advances in standardization of radiographic cardiac substructure deﬁnition offer a common basis for comparison
and should lead to better understanding of how radiation
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Fig. 4 (A) Utilization rates of 3-dimensional conformal radiation therapy (3D-CRT) and intensity modulated radiation
therapy (IMRT) before (2012-2016) and after (2017-2020) targeted interventions aimed at reducing cardiac dose. (B)
Mean heart dose (MHD) analyzed by treatment modality in each temporal cohort. Abbreviation: N Obs = number
observed.

to individual substructures affects the risk of future cardiac events.14
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